[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Galapagos NV ADR (GLPG)

Galapagos NV ADR (GLPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Galapagos Heads Into Earnings With Analyst Optimism Rising—But Revenue Trajectory Remains Unclear

Galapagos NV (GLPG) reports Q1 2026 earnings after market close on May 6, 2026, with analysts expecting a loss of $1.27 per share on revenue of $24.9 million. The central question is whether the biotechnology company can demonstrate progress in its pipeline and commercial execution following a volatile 2025 that saw dramatic swings in profitability. With the stock trading below all major moving averages and a unanimous sell signal from technical indicators, investors will scrutinize whether management can articulate a path back to sustainable growth.

Galapagos NV is a Belgium-based biotechnology company focused on discovering, developing, and commercializing small molecule medicines for inflammatory diseases, fibrotic diseases,...

Fundamentals

See More
  • Market Capitalization, $K 1,875,429
  • Shares Outstanding, K 65,897
  • Annual Sales, $ 1,258 M
  • Annual Income, $ 363,050 K
  • EBIT $ -203 M
  • EBITDA $ -140 M
  • 60-Month Beta 0.25
  • Price/Sales 1.47
  • Price/Cash Flow 38.56
  • Price/Book 0.59

Options Overview Details

View History
  • Implied Volatility 56.45% (+0.22%)
  • Historical Volatility 29.88%
  • IV Percentile 34%
  • IV Rank 27.96%
  • IV High 132.05% on 11/10/25
  • IV Low 27.11% on 08/18/25
  • Expected Move (DTE 10) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 62
  • Put/Call OI Ratio 97.31
  • Today's Open Interest 6,292
  • Open Int (30-Day) 6,165
  • Expected Range 28.41 to 28.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.27
  • Number of Estimates 1
  • High Estimate $-1.27
  • Low Estimate $-1.27
  • Prior Year $-2.47
  • Growth Rate Est. (year over year) +48.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.49 +3.27%
on 04/29/26
29.77 -4.64%
on 04/06/26
-1.03 (-3.50%)
since 04/02/26
3-Month
27.49 +3.27%
on 04/29/26
36.24 -21.66%
on 02/24/26
-4.99 (-14.95%)
since 02/05/26
52-Week
24.74 +14.78%
on 05/13/25
37.78 -24.85%
on 10/03/25
+1.24 (+4.57%)
since 05/05/25

Most Recent Stories

More News
Galapagos Heads Into Earnings With Analyst Optimism Rising—But Revenue Trajectory Remains Unclear

Barchart Research What to Expect from GLPG Earnings GLPG Generated May 5, 2026 Current Price $28.39 EPS Estimate $$-1.27 Consensus Rating Moderate Sell Average Move 2.55% Galapagos Heads Into Earnings...

GLPG : 28.39 (-0.25%)
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galapagos (GLPG – Research Report), Pharvaris (PHVS – Research Report) and Stevanato Group (STVN –...

PHVS : 30.02 (unch)
GLPG : 28.39 (-0.25%)
STVN : 18.21 (+2.36%)
Kepler Capital Remains a Sell on Galapagos (0JXZ)

Kepler Capital analyst Christophe dombu maintained a Sell rating on Galapagos on October 2 and set a price target of €23.50. The company’s shares closed last Thursday at €30.50.Elevate Your Investing...

GLPG : 28.39 (-0.25%)
Galapagos Updates on Cell Therapy Business Strategic Review

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

GLPG : 28.39 (-0.25%)
Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed

The company expects to announce a new CFO “in the coming months.”

SBIO : 55.29 (+0.18%)
SPDW : 49.19 (+1.67%)
GLPG : 28.39 (-0.25%)
Galapagos Stock Surges On Strategic Spin-Off And Restructuring Plans: Retail Turns Extremely Bullish

The Belgium-based biotech company said it would reduce its workforce by 40%, eliminating about 300 positions across Europe.

GILD : 133.48 (+0.60%)
GLPG : 28.39 (-0.25%)
+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

/PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as...

GLPG : 28.39 (-0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

3rd Resistance Point 29.20
2nd Resistance Point 28.98
1st Resistance Point 28.68
Last Price 28.39
1st Support Level 28.16
2nd Support Level 27.94
3rd Support Level 27.64

See More

52-Week High 37.78
Fibonacci 61.8% 32.80
Fibonacci 50% 31.26
Fibonacci 38.2% 29.72
Last Price 28.39
52-Week Low 24.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.